This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Rocket Stocks to Buy This Earnings Season

Johnson & Johnson

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Johnson & Johnson ( JNJ) is having a stellar year in 2013. Shares of the healthcare giant have rallied more than 27% since the start of the year, around double what the venerable S&P 500 has managed to accomplish over the same time period. Johnson's set to announce its earnings numbers tomorrow.

>>5 Big Stocks to Trade for Big Gains

Johnson & Johnson is the prototypical blue-chip stock. The $252 billion firm pays out just shy of a 3% dividend yield, and it's got a model that works well in good times and in bad ones. The business includes everything from consumer products such as Band-Aid brand bandages to pharmaceuticals and medical devices.

While pharma makes up a large chunk of the firm's net income, the consumer and medical device segments offer investors diversification that few big pharma names can match -- especially as patent drop-offs plague valuations in the industry.

JNJ is a big beneficiary of changing demographics. As the baby boomer population in the developed world gets older, medical costs are expected to inflate in kind, and that's a good thing for pharma-driven firms such as Johnson & Johnson. Elsewhere, burgeoning younger populations in emerging markets are there to pick up the demand for its consumer products.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
BA $132.08 0.91%
EL $93.28 0.14%
EOG $81.26 2.42%
JNJ $112.88 0.59%
KMB $127.36 -0.45%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs